Research Terms
1. Tong XW, Block A, Chen SH, Contant CF, Agoulnik I, Blankenburg K, Kaufman RH, Woo SL, Kieback DG, In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol 61: 2, 175-9, May, 1996.
2. Kent-First MG, Maffitt M, Muallem A, Brisco P, Shultz J, Ekenberg S, Agulnik AI, Agoulnik I, Shramm D, Bavister B, Abdul-Mawgood A, VandeBerg J, Gene sequence and evolutionary conservation of human SMCY, Nat Genet 14: 2, 128-9, Oct, 1996.
3. Tong XW, Agoulnik I, Blankenburg K, Contant CF, Hasenburg A, Runnebaum LB, Stickeler E, Kaplan AL, Woo SL, Kieback DG, Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy., Anticancer Res 17: 2A, 811-3, Mar-Apr, 1997.
4. Agoulnik IU, Cho Y, Niederberger C, Kieback DG, Cooney AJ, Cloning, expression analysis and chromosomal localization of the human nuclear receptor gene GCNF., FEBS Let 424: 1-2, 73-8, Mar 6, 1998.
5. Tong XW, Engehausen DG, Kaufman RH, Agoulnik I, Contant C,
6. Tong X, Engehausen DG,
7. Levy T, Agoulnik I, Atkinson EN, Tong XW, Gause HM, Hasenburg A, Runnebaum IB, Stickeler E, Mobus VJ, Kaplan AL, Kieback DG, Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients., Anticancer Res 18: 3A, 1345-9, May-Jun, 1998.
8. Tong X, Shine DH, Agoulnik I, Freund CT, Hasenburg A, Aguilar-Cordova E, Woo SL, Kieback DG, Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovariancancer cells to chemotherapeutic agents. Anticancer Res 18:5A, 3421-6, Sep-Oct, 1998.
9. Tong X, Engehausen DG, Freund CT, Agoulnik I, Oehler MK, Kim TE, Hasenburg A, Guo Z, Contant CF, Woo SL, Kieback DG, Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. Hybridoma 18:1, 93-7, Feb, 1999.
10. Bishop CE, Whitworth DJ, Qin Y, Agoulnik AI, Agoulnik IU, Harrison WR, Behringer RR, Overbeek PA, A transgenic insertion upstream of sox9 is associated with dominant XX sex reversal in the mouse. Nat Genet 26:4, 490-4 Dec, 2000.
11. James AJ, Agoulnik IU, Harris JM, Buchanan G, Tilley WD, Marcelli M, Lamb DJ, Weigel NL, A Novel Androgen Receptor Mutant, A748T, Exhibits Hormone Concentration-Dependent Defects in Nuclear Accumulation and Activity Despite Normal Hormone-Binding Affinity., Mol Endocrinol 16:12, 2692-705 Dec, 2002
12. Weigel NL and Agoulnik IU (2003) Steroid Receptor Crosstalk with Cellular Signalling Pathways. Encyclopedia of hormones Academic Press. Elsevier Science
13. Koshkina NV, Agoulnik IU, Melton SL, Densmore CL, Knight V (2003) Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes:optimization of pulmonary delivery and retention. Molecular Therapy 8:2; 249-54 Aug, 2003
14. Agoulnik IU, Krause WC, Bingman WE 3rd, Rahman HT, Amrikachi M, Ayala GE, Weigel NL (2003) Repressors of androgen and progesterone receptor action. J Biol Chem 278:33; 31136-48 Aug, 2003
15. Agoulnik IU, Tong XW, Fischer DC, Koerner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL, Kieback DG (2004) A Germline Variation in the Progesterone Receptor Gene Increases Transcriptional Activity and May Modify Ovarian Cancer Risk. The Journal of Clinical Endocrinology & Metabolism 89:12; Dec, 2004
16. Murthy S, Agoulnik IU, Weigel NL. Androgen Receptor Signaling and Vitamin D Receptor Action in Prostate Cancer Cells. Prostate. 1:64;362-72 Sep, 2005
17. Agoulnik IU, Vaid A, Bingman WE III, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. A Role for SRC-1 in Promoting Prostate Cancer Cell Growth and Tumor Progression. Cancer Research. 1:65;7959-67 2005 Sep, 2005
18. Dai H, Li R, Wheeler T, de Vivar AD, Chen X, Frolov A, Agoulnik IU, Thompson T, Rowley D, Ayala G. Pim-2 Upregulation: Biological Implications Associated with Perinueral Invasion and Disease Progression in Prostate Cancer. Prostate. 1:65;276-86 Nov, 2005
19. Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI. The Role of Relaxin in Endometrial Cancer. Cancer Biol Ther. 31:5; 71-7 Jan, 2006
20. Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, Weigel NL, Moran T, Mikic I, Price JH, Mancini MA. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem. 98:4; 770-88 Jan, 2006
21. Agoulnik IU, Weigel NL. Androgen Receptor Action in Androgen Dependent and Recurrent Prostate Cancer. J Cell Biochem. 99:2;362-72 Oct, 2006
22. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE III, Erdem H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. Androgen Receptor Coactivator TIF2 Expression, Biochemical Recurrence and Androgen
23. Agoulnik IU, Weigel NL. Androgen Receptor Coactivators and Prostate Cancer. Hormonal Carcinogenesis, Volume V. 5th International Symposium on Hormonal Carcinogenesis. 2006
24. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI. Relaxin promotes prostate cancer progression. Clin Cancer Res, 13:6;1695-702 March, 2007.
25. Feng S, Bogatcheva NV, Truong A, Korchin B, Bishop CE, Klonisch T, Agoulnik IU, Agoulnik AI. Developmental expression and gene regulation of insulin-like 3 receptor RXFP2 in mouse male reproductive organs. Biol Reprod, 77:4;671-80. Oct, 2007.
26. Agoulnik IU, Weigel NL. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol, 617:245-55. 2008
27. Agoulnik IU, Nakka M, Weigel NL. Target Gene Specific Regulation of Androgen Receptor Activity by p42/p44 MAPK. Mol Endo, 22(11):2420-32. Nov, 2008.
28. Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AI. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 1160:379-80. Apr, 2009.
29. Li Z, Burzawa JK, Troung A, Feng S, Agoulnik IU, Tong X, Anderson ML, Kovanci E, Rajkovic A, Agoulnik AI. Relaxin signaling in uterine fibroids. Ann N Y Acad Sci. 1160:374-8. Apr, 2009.
30. Agoulnik IU, Weigel, NL. Coactivator Selective Regulation of Androgen Receptor Activity. Steroids, 74(8):669-74. Aug, 2009.
31. Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 17(4):1021-33. Dec, 2010.
32. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL, Agoulnik IU. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 71(2):572-82. Jan, 2011.
33. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: the New Kid on the PI3K Block. Oncotarget. Apr. 2011.
Endocrine Society, Member; 1998 - 2011
American Association for Cancer Research (AACR), Member; 1998 - 2011
Pathobiology Section , Prostate Cancer Research Program (PCRP); 2010 - 2010
PLoS ONE, PLoS OONE; 2010 - 2011
Health sciences, Republic of Italy, Ministry of Labor, Health and Social Policies, Department of Innovation; 2009 - 2011
Recovery Act Limited Competition for NIH Grants: Research and Research Infrastructure “Grand Opportunities” (RC2), NCI RFA-OD-09-004; 2009 - 2009
Concept Revisions Review , NCI ARRA ; 2009 - 2009
10. Role of AR Coregulators in Prostate Cancer Progression; University of Pittsburgh, Department of Urology, Pittsburg, PA; 2007
11. Functional Consequences of NCoR Loss in Prostate Cancer; Prostate SPORE meeting; Baylor College of Medicine, Houston, TX; 2007
12. NCoR is a key coregulator of AR action in prostate and prostate cancer; Roswell Park Cancer Institute, Buffalo, NY; 2007
13. Androgen Receptor Coregulators in Prostate Cancer; Distinguished guest lecturer; The Chinese University of Hong Kong; 2010
14. Androgen regulated Expression of Tumor Suppressor in Normal and Malignant Prostate.; Distinguished guest lecturer ; Tongji University, Shanghai, China; 2010
15. AR coregulators as therapeutic targets in prostate cancer.; Univercity of Miami School of Medicine; 2010
AR signaling in prostate cancer progression; FIU Deparment of Chemistry and Biochemistry, Miami, FL; 2010